Browse the evidence

SGLT2 inhibitors reduce oxidative stress and inflammation in cardiac tissue by improving nitric oxide bioavailability, stimulating Nrf2/ARE signaling, and suppressing NADPH oxidase.

SGLT2 inhibitors help protect heart cells from damage caused by oxidative stress and inflammation, which contributes to their ability to prevent heart failure.

SGLT2 inhibitors reduce the incidence of atrial fibrillation (AF) and atrial flutter (AFL) by reducing atrial dilation, intracellular sodium/calcium levels, and epicardial adipose tissue.

Taking SGLT2 inhibitors may lower your risk of developing irregular heartbeats like atrial fibrillation, which is a common complication in diabetes and heart failure.

GLP-1 receptor agonists reduce stroke risk but do not significantly prevent the onset of atrial fibrillation or atrial flutter, and may increase heart rate.

GLP-1 RAs are effective at reducing stroke risk, but unlike SGLT2 inhibitors, they do not appear to prevent atrial fibrillation and may slightly increase heart rate.

Fibroblast growth factor 21 (FGF21) acts as a specific negative feedback signal that reduces carbohydrate (sweet) preference in response to high sugar intake.

High sugar intake triggers the release of FGF21, a hormone that naturally reduces your desire for sweets. Consistently high sugar intake may blunt this system or require higher thresholds to trigger it. Reducing initial sugar loads may help restore this natural regulatory feedback loop.

GLP-1 receptor agonists (GLP-1 RAs) induce significant gastrointestinal adverse events (nausea, vomiting, diarrhea, constipation) by slowing gastric emptying and increasing gastric accommodation, with incidence rates ranging from 18% to 52% depending on the specific agent and dose.

If you are prescribed a GLP-1 drug like semaglutide or liraglutide, expect a high chance of nausea or vomiting, especially when starting. The paper advises starting at the lowest dose and increasing slowly. Crucially, you must adjust your diet: eat smaller meals, reduce fat, and avoid raw fiber. If you continue to have side effects, ask your doctor about dose de-escalation. Do not assume the sickness is what causes the weight loss; the drug works directly, but the side effects are a common hurdle to manage.

GLP-1 receptor agonists delay gastric emptying and increase gastric accommodation, which contributes to satiety but poses a significant risk of aspiration during perioperative procedures, necessitating specific preoperative management guidelines.

If you are having surgery and take a weekly GLP-1 shot (like Ozempic or Wegovy), tell your surgeon and anesthesiologist. For elective surgery, you may need to stop the drug 4 weeks beforehand. If it's an emergency, they will check your stomach with an ultrasound and may give you a drug (erythromycin) to empty it. This is a new standard of care to prevent choking on stomach contents during anesthesia.

Some GLP-1RAs (e.g., Lixisenatide, Exenatide, oral Semaglutide) show neutral cardiovascular outcomes in patients with Type 2 Diabetes, suggesting that not all GLP-1RAs provide cardiovascular protection.

Not all GLP-1 medications protect the heart. Drugs like Lixisenatide, Exenatide, and oral Semaglutide have shown neutral effects on major cardiovascular events in large studies. If you have heart disease, ask your doctor if your specific GLP-1 medication has proven cardiovascular benefits.

High-dairy-protein diets with variable carbohydrate and fat ratios provide no advantage for fat loss or lean mass preservation compared to a control diet when both are combined with energy restriction and exercise.

If you are overweight and want to lose fat while keeping muscle, eat a high-protein diet (around 30% of calories) from dairy sources, create a moderate calorie deficit (500 kcal/day), and exercise regularly (resistance and cardio). You do not need to strictly limit carbohydrates or fats to see good results; the total protein amount and energy deficit matter more than the specific ratio of carbs to fat.

In overweight or obese adults with diabetes, unintentional or general weight loss is associated with a statistically significant increase in all-cause and cardiovascular disease mortality compared to weight stability.

If you have diabetes and are overweight or obese, do not pursue weight loss unless it is explicitly intentional and monitored, as general weight loss is linked to higher mortality in this group. Focus instead on glycemic control and avoiding muscle loss. Consult your endocrinologist before attempting any weight reduction strategy.

In patients with established incident cardiovascular disease, higher body mass index (overweight and obesity) is associated with a more favorable prognosis for subsequent stroke, peripheral vascular disease, and mortality (CVD-related and all-cause) compared to normal BMI, regardless of metabolic health status.

If you have had a heart attack, stroke, or peripheral vascular disease, being overweight or obese is not necessarily a bad thing for your survival. In fact, this large study shows that having extra weight is linked to a lower risk of dying from heart issues or other causes compared to being normal weight. Do not aggressively try to lose weight without consulting your doctor, as maintaining energy reserves might be protective. Instead, focus on controlling blood pressure, cholesterol, and diabetes.

In patients with incident cardiovascular disease, increasing the number of metabolic risk factors (hypertension, dyslipidemia, diabetes) is associated with increased risk of subsequent non-fatal coronary heart disease (CHD) and incident heart failure (HF), regardless of BMI.

While having extra weight might help you survive a heart event, having high blood pressure, high cholesterol, or diabetes makes it much more likely you will have another heart attack or develop heart failure. You must manage these metabolic risk factors aggressively, regardless of your weight.

Implementing FDA voluntary sodium reduction targets in processed foods yields a net positive economic and health benefit for the broader food system workforce, primarily through reduced cardiovascular disease incidence and healthcare costs.

For policymakers and industry leaders: Implementing gradual, national sodium reduction targets in processed foods is economically beneficial for the food system as a whole. The health savings and productivity gains for workers outweigh the costs of reformulation. For consumers: Gradual sodium reduction in processed foods does not significantly impact taste or sales because human taste adapts over time. The primary benefit is a reduction in cardiovascular disease risk.

For workers specifically in the processed food industry, the net monetary benefit of sodium reformulation is negative, meaning the costs of reformulation exceed the health-related cost savings realized by this specific subgroup.

For processed food industry executives: Sodium reformulation may not be economically beneficial for your specific workforce in the short-to-medium term, as the costs of reformulation exceed the health savings for your employees. However, for the broader food system, it is beneficial. Policymakers should consider incentives to offset these costs for the processed food industry.

Ketogenic diets (KD) do not independently reduce energy intake or increase energy expenditure compared to non-ketogenic diets when energy density and behavioral factors are controlled; any observed weight loss is attributable to caloric deficit rather than ketosis itself.

If you are choosing a diet for weight loss, know that a ketogenic diet is not metabolically superior to a high-carbohydrate diet in terms of appetite control or energy expenditure. You will lose weight on either diet if you maintain a caloric deficit. Do not expect ketones to magically suppress your hunger or boost your metabolism beyond what is achieved by simply eating fewer calories.

Intensive lifestyle interventions (ILI) for weight loss in type 2 diabetes require high financial investment ($2,865/year in year 1) driven primarily by personnel costs, which decreases over time as intervention intensity declines.

If you are considering a structured weight loss program for type 2 diabetes, expect to pay significantly more than self-directed efforts, especially in the first year. The cost is driven by frequent visits with dietitians and exercise specialists. However, this investment often pays off through reduced medication needs and fewer hospital visits over time. Look for programs that offer a mix of group and individual support, as these tend to be more cost-effective per person than purely individual coaching.

Anti-obesity medications (GLP-1 RAs, MC4R agonists) and bariatric surgery work by improving appetite control and resetting the fat mass set point, rather than just creating a caloric deficit.

Medications like GLP-1 agonists and surgeries like gastric bypass succeed because they fix the broken biological signals in your brain that tell you when to stop eating. They improve appetite control, making it easier to maintain weight loss without constant willpower.

Short-term calorie restriction (12 weeks) does not reverse the accumulation of effector memory T cells in subcutaneous adipose tissue (SAT) or reduce local inflammatory cytokine levels in obese postmenopausal women, despite inducing weight loss and improving insulin sensitivity.

For obese postmenopausal women, short-term calorie restriction (12 weeks) improves insulin sensitivity but does not reduce inflammation in fat tissue. The immune cells in fat (effector memory T cells) and inflammatory cytokines remain high despite weight loss. This suggests that weight loss alone may not be sufficient to resolve chronic low-grade inflammation in the short term, and longer-term strategies or additional interventions might be needed to target adipose immune cells.

High-temperature cooking and prolonged storage can decrease protein quality by reducing the bioavailability of essential amino acids, particularly lysine, through the Maillard reaction and protein aggregation.

Avoid charring or overcooking meats and grains. High-temperature methods like grilling or prolonged roasting can chemically alter amino acids (especially lysine), reducing the protein's quality. Moderate cooking is generally better for preserving bioavailability.

Metformin treatment alters gut microbiota composition (increasing Escherichia coli, decreasing Intestinibacter bartlettii) to enhance the production of short-chain fatty acids (propionate and butyrate) and modulate bile acid pools, which mediates glucose-lowering effects.

If you take metformin, your gut bacteria are actively helping lower your blood sugar by producing beneficial fats (SCFAs) and signaling molecules. However, this same bacterial shift can cause stomach upset for about 30% of users. If you experience GI distress, it may be linked to this mechanism, and discussing management strategies with your provider is important.

Performing resistance exercise during the follicular phase (high estrogen) does not yield greater muscle protein synthesis or myofibrillar protein breakdown compared to the luteal phase (high progesterone) in naturally cycling women.

You do not need to schedule your resistance training around your menstrual cycle to maximize muscle growth. Whether you are in your follicular (high estrogen) or luteal (high progesterone) phase, your muscles respond to resistance exercise similarly in terms of protein synthesis and breakdown. Consistency in your training program is more important than trying to time your workouts with specific hormonal phases.

Integrating multiple computational gene prioritization methods (SMR, FINEMAP, DEPICT, MAGMA, TWAS, MSC, PoPS, nearest gene) identifies 292 high-confidence candidate genes associated with BMI, many of which regulate neuronal body weight control, circadian rhythm, insulin secretion, and glucose homeostasis.

This research does not offer a direct lifestyle intervention but highlights that obesity has strong genetic underpinnings involving brain regulation, insulin, and circadian rhythms. Understanding these specific biological pathways can help explain why weight loss is difficult for some and points toward future targeted therapies (e.g., drugs affecting GIPR or FGFR1) rather than just willpower-based approaches.

Combined pharmacological administration of oxytocin (OT) and a selective CCKAR agonist (A-71263) produces greater weight loss and fat mass reduction than either agent alone in diet-induced obese mice.

Combining oxytocin with a CCK receptor agonist is more effective for weight loss than using either drug alone. This suggests that future obesity treatments might need to target multiple pathways simultaneously to overcome diet-induced resistance.

Central nervous system atypical protein kinase C (aPKC) activity, specifically the PKC-l isoform in POMC neurons, is required to constrain food intake and prevent diet-induced obesity and glucose intolerance.

This research highlights that obesity is not just about calories in vs. calories out, but involves specific brain signaling pathways (like aPKC in POMC neurons) that regulate hunger. Disrupting these pathways can lead to increased food intake and weight gain, even if the diet is high-fat. This suggests that targeting these neural mechanisms could be a potential therapeutic strategy for obesity.

GLP-1RAs exert their therapeutic effects through complex intracellular signaling pathways, specifically activating ERK1/2, AMPK, cAMP, MAPK, and PKC, which regulate insulin secretion, cell proliferation, and inflammation.

The effectiveness of GLP-1 medications is driven by their ability to activate specific cellular pathways (ERK1/2, AMPK, cAMP, MAPK, PKC). These pathways control insulin release, cell growth, and inflammation, which is why these drugs work for both diabetes and potentially other conditions like cancer or cardiovascular disease.